Evaluation of treatments for the vaccination against hepatitis B + thymopentine.
We have studied a series of 43 patients--who were suffering from uremia, subject to hemodialysis treatment, resulting seronegative to the test for HBV and who had never been vaccinated before--considering the HBS antibody as seroconversion index. We subdivided our patients into three groups, according to the treatment employed. First group: French vaccine; 2nd group: French vaccine+thymopenthine; 3rd group: recombining DNA vaccine+thymopentine. From a statistical point of view, in the 3rd group we obtained a significant seroconversion in terms of patients, if compared with the other groups.
Ervo
R
R
Department of Nephrology and Dialysis, USL N.1, Liguria-Ventimiglia, Italy.
Faletti
P
P
Magni
S
S
Cavatorta
F
F
D000328:Adult; D000368:Aged; D005069:Evaluation Studies as Topic; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D016305:Thymopentin / Q000008:administration & dosage*; D014511:Uremia / Q000276:immunology / Q000628:therapy; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage*
D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines; D016305:Thymopentin